Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Etiracetam
- Development stage
- Unknown
- Lead developer
- UCB
- Modality
- Small Molecules
- Administration
- Oral, Intravenous, Subcutaneous
01
Overview
Etiracetam is a chemical compound belonging to the racetam family, developed as a nootropic drug. It is a pyrrolidinone and acetamide derivative. It is the racemic equivalent of Levetiracetam, its biologically active S-enantiomer, which is marketed as an antiepileptic drug.
- Other names
- (RS)-2-(2-oxopyrrolidin-1-yl)butanamide
02
Targets
SV2A (Synaptic vesicle glycoprotein 2A)HTR3A (5-hydroxytryptamine receptor 3A)CACNA1B (Voltage-dependent N-type calcium channel subunit alpha-1B)AChR (Acetylcholine receptor)
Beyond the preview
Go deeper on Etiracetam.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Etiracetam.